Bellicum Pharmaceuticals Inc. buy klostergang
Summary
This prediction ended on 20.05.19 with a price of €26.43. Massive losses of -74.89% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Bellicum Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | 1.164% | 1.549% | 24.351% | 23.659% |
iShares Nasdaq 100 | 0.118% | 0.969% | 28.865% | 41.786% |
iShares Nikkei 225® | 1.124% | -1.120% | 17.443% | 6.454% |
iShares S&P 500 | 0.479% | 1.068% | 28.585% | 42.511% |
Comments by klostergang for this prediction
In the thread Bellicum Pharmaceuticals Inc. diskutieren
klostergang stimmt dem Sentiment von 'Buy' zu
The June 26, 2017 updated results Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) presented for BPX-501, validated its controllable cell therapy platform. This, according to the firm, is supportive of a potential new standard of care in haploidentical stem cell transplant.
BPX-501 is an allogenic T cell add-back product used after a T-cell depleted haploidentical allogenic hematopoietic stem cell transplant for both benign and malignant hematologic diseases.
As such, Wells Fargo has an Outperform rating on the shares of Bellicum, with a $31 price target.
The comment has been deleted
Stopped prediction by klostergang for Bellicum Pharmaceuticals Inc.
Bellicum Pharmaceuticals Inc.
15.03.20
04.11.21
17.06.21
Bellicum Pharmaceuticals Inc.
13.02.20
25.02.20
25.02.20
Bellicum Pharmaceuticals Inc.
22.05.19
26.11.19
26.11.19